Cryoport, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 08, 2023 at 04:32 pm EST
Share
Cryoport, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 56.16 million compared to USD 60.46 million a year ago. Net loss was USD 13.27 million compared to USD 5.32 million a year ago. Basic loss per share from continuing operations was USD 0.31 compared to USD 0.15 a year ago.
For the nine months, revenue was USD 176 million compared to USD 176.92 million a year ago. Net loss was USD 37.2 million compared to USD 27.9 million a year ago. Basic loss per share from continuing operations was USD 0.89 compared to USD 0.69 a year ago.
Cryoport, Inc. is engaged in supply chain solutions for cell and gene therapies. The Companyâs supply chain solutions enable manufacturers, contract manufacturers (CDMOâs), contract research organizations (CROâs), developers, and researchers to carry out their business with certainty. The Company provides a broad array of supply chain solutions for the life sciences industry. Through its platform of critical products and solutions, including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, the Company is enabling the future of medicine worldwide, through its systems, compliant procedures, and approach to supply chain management. Its products and services include Cryoport Express Shippers, Cryoport ELITE Shipper Systems, Cryoport Consulting Services, Cryoport Bioservices, CRYOGENE, CRYOPDP Temperature-controlled Logistics, Cryoport Cryoshuttle, IntegriCell Services, Tec4Med, and others.
CRYOPORT, INC. 
